Melanoma vaccines: Breakthrough or bust?

Cancer Investigation

Volumn 20, Issue 7-8, 2002, Pages 1114-1116

  Sabel, Michael S ^a   Sondak, Vernon K ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MELACINE; MELANOMA VACCINE;

EDITORIAL; FATIGUE; HUMAN; IMMUNE RESPONSE; MELANOMA; MYALGIA; PRIORITY JOURNAL; SKIN MANIFESTATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 0036425352     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120005930     Document Type: Editorial

References (6)

1. Perales, M.A.; Wolchok, J.D. Melanoma vaccines. Cancer Investig. 2002, 20 (7&8), 1012-1026.
2. Livingston, P. The Unfulfilled promise of melanoma vaccines. Clin. Cancer Res. 2001, 7, 1837-1838.
3. Kirkwood, J.M.; Strawderman, M.H.; Ernstoff, M.S.; Smith, T.J.; Bordern, E.C.; Blum, R.H. interferon Alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 1996, 14, 7-17.
4. Kirkwood, J.M.; Ibrahim, J.G.; Sosman, J.A.; Sondak, V.K.; Agarwala, S.S.; Ernstoff, M.S.; Rao, U. High-dose interferon Alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup Trial E1694;S9512,/C509801. J. Clin. Oncol. 2001, 19 (9), 2370-2380.
5. Mitchell, M.S.; Harel, W.; Groshen, S. Association of HLA Phenotype with response to active specific immunotherapy of melanoma. J. Clin. Oncol. 1992, 10, 1158-1164.
6. Sondak, V.K.; Liu, P.-Y.; Tuthill, R.J.; Kempf, R.A.; Unger, J.M.; Sosman, J.A.; Thompson, J.A.; Weiss, G.R.; Redman, B.G.; Jakowatz, J.G.; Noyes, R.D.; Flaherty, L.E. Adjuvant immunotherapy of resected, intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group. J. Clin. Oncol. 2002, 20 (8), 2058-2066.